Clinical trials: Dupilumab
Atopic Dermatitis
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated…
- Trial name
- NCT05694884
- Testing
- ASLAN004
- Where
- 27 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- ASLAN Pharmaceuticals
Atopic Dermatitis
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01548404
- Testing
- Dupilumab
- Where
- 21 sites in Czechia, France and 3 more
- Volunteers
- 109 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD
This prospective, real-world observational study (T2AIR Study) evaluates the long-term efficacy and safety of six biologics targeting Type 2 inflammation - omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and…
- Trial name
- T2AIR (NCT07823842)
- Testing
- Biologics targeting Type 2 inflammation, Patients with asthma and copd who received standard of care
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Healthy
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers
This study will test the safety and tolerability (how the body reacts to the drug) of REGN668 and placebo (an inactive substance that contains no medicine) in healthy subjects.
- Trial name
- NCT01015027
- Testing
- REGN668
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Lichen Simplex Chronicus
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged…
- Trial name
- NCT06687980
- Testing
- Dupilumab
- Where
- 63 sites in United States, Argentina and 15 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Asthma
Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.
In asthmatics with airway hyperresponsiveness and a "T2 immune signature" (type 2), Dupilumab will suppress airway hyperresponsiveness (assessed by methacholine PC20 ≤ 4 mg/mL (PC20: provocative concentration causing a 20% fall…
- Trial name
- NCT03884842
- Testing
- Dupilumab/Dupixent
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- McMaster University
Chronic Rhinosinusitis (Diagnosis), COVID-19
The Nasal Microbiome and Its Importance in Disease
Methods: all studies are case control studies on six different groups: normal individuals, non-COVID-19 patients with olfactory dysfunction, COVID-19 positive patients, previous COVID-19 positive patients with prolonged olfactory…
- Conditions
- Chronic Rhinosinusitis (Diagnosis), COVID-19, Anosmia
- Trial name
- NCT05061329
- Where
- Denmark
- Volunteers
- 619 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Pruritus
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
- Trial name
- NCT04256759
- Testing
- Dupilumab 300Mg Solution for Injection
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease…
- Trial name
- NCT04430179
- Testing
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of South Florida
Asthma, Allergic, Asthma
IL13 Signaling in Allergic Asthma
This study will investigate the role of dupilumab in the treatment of asthma with comorbid obesity. It is hypothesized that in airway epithelial cells, unique transcriptomic and proteomic expression patterns distinguish allergic…
- Conditions
- Asthma, Allergic, Asthma, Obesity
- Trial name
- NCT05478824
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Duke University
Dermal Hypersensitivity Reaction
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction.
- Trial name
- NCT06012448
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Michigan
Congenital Ichthyosis
Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
This is an experimental non-randomized clinical study aimed at expanding the indications for the use of biological drugs with the aim of using them for the pathogenetic therapy of children with congenital ichthyosis.
- Trial name
- NCT04996485
- Testing
- Secukinumab Injection, Ustekinumab Injection, Dupilumab Injection
- Where
- Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
Atopic Dermatitis (AD)
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S.
- Trial name
- NCT07411755
- Testing
- GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent®
- Where
- China
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd
Asthma
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma
The purpose of this retrospective medical record review is to describe the real-world clinical effectiveness of dupilumab with patients in the United Kingdom with severe asthma.
- Trial name
- DUPIAZA (NCT06064526)
- Testing
- No intervention
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Sanofi
Atopic Dermatitis, Atopic Dermatitis (AD)
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Patients
- Trial name
- NCT07448363
- Testing
- Abrocitinib, Upadacitinib, Baricitinib
- Where
- Costa Rica
- Volunteers
- 50 people
- Sponsor
- Caja Costarricense de Seguro Social
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a sino-nasal chronic inflammatory disease that strongly affects patients' quality of life, especially in difficult-to-treat cases.
- Trial name
- DUPIREAL (NCT05529784)
- Testing
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Where
- 19 sites in Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-Small Cell Lung Cancer
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT06088771
- Testing
- Dupilumab, Cemiplimab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pruritus
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies…
- Trial name
- NCT05263206
- Testing
- Dupilumab, Fexofenadine (loratadine if not available)
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 284 people
- Sponsor
- Sanofi
Asthma
DETACT sEvere asThmAtiC paTients - a Pilot Study
The objective of this study is to investigate the effect of dupilumab treatment on mucus plugging in severe asthma patients with severe eosinophilic asthma.
- Trial name
- DETACT (NCT07025200)
- Testing
- Dupilumab
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna